Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
May 22 2024 - 4:15PM
Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a
pioneering force in medical aesthetics, announced that Chief
Executive Officer Dr. Jordan R. Plews, PhD will be presenting at
the Los Angeles Bioscience Ecosystem Summit Twenty
24 (“LA-BEST”) conference on Thursday May 23, 2024.
LA-BEST is the premier showcase for bioscience
innovation hosted by UCLA Technology Development Group (UCLA TDG).
The event is a collaboration of ~1,000 participants across the Los
Angeles area to promote biotech innovation and to foster
partnerships between academic institutions, the investment
community, and the biopharma industry. Leading bioscience
translational research programs and startups will be showcased
where Southern California Institutions have significant expertise,
pioneering research, and resource commitments directed toward
developing innovative patient therapies.
Details
- What: UCLA
LA-BEST 2024 Conference
- Where: Luskin
Conference Center on the UCLA Campus
-
When: Thursday May 23, 2024
- Website:
https://tdg.ucla.edu/news-events/events/labest-2024
Dr. Plews will speak as part of the session
titled “Hot Topic: Metabolism”, where invited panelists will
discuss the current gaps in obesity knowledge and technology, and
emerging solutions. Dr. Plews will be presenting Elevai
Biosciences’ engineered probiotic approach for muscle loss
prevention in combination with one or more GLP-1 receptor agonists
in obesity.
“Myostatin is being tested in combination with
GLP-1 drugs as it’s demonstrated to be a clinically validated
target with potential in muscle mass and strength building,"
said Dr. Jordan R. Plews, PhD Chief Executive Officer of
Elevai. "I’m excited to share with the scientific and investment
community at LA-BEST why we believe that our lead clinical
candidate EL-22 offers a differentiated, oral approach as compared
to other myostatin strategies being tested in obesity. Our approach
induces mucosal immunity through the body’s own anti-myostatin
antibodies, which could have an important role in addressing the
unmet medical need of obese patients, who need to preserve muscle
while losing weight.”
About Elevai Labs, Inc.Elevai
Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and
biopharmaceutical drug development, focusing on innovations for
skin aesthetics and treatments tied to obesity and metabolic
health. Driven by a commitment to scientific research, we aim to
transform personal health and beauty. For more information, please
visit www.elevailabs.com.
About Elevai BiosciencesElevai
Biosciences Inc., an Elevai Labs company, is a biopharmaceutical
company focusing on the development and acquisition of cutting-edge
aesthetic medicines. Our lead asset, EL-22, is leveraging a
first-in-class engineered probiotic approach to address obesity’s
pressing issue of preserving muscle while on weight loss
treatments, including GLP-1 receptor agonists. For more
information, please visit www.elevaibio.com.
Forward-Looking Statements
Certain statements in this announcement are
forward-looking statements, including, but not limited to, the
Company's proposed Offering. These forward-looking statements
involve known and unknown risks and uncertainties and are based on
the Company's current expectations and projections about future
events that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs, including the expectation that our shares of common stock
will start trading or that the Offering will be successfully
completed. Investors can find many (but not all) of these
statements using words such as "approximates," "believes," "hopes,"
"expects," "anticipates," "estimates," "projects," "intends,"
"plans," "will," "would," "should," "could," "may" or other similar
expressions in this prospectus. The Company undertakes no
obligation to update or revise publicly any forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's registration statement and other filings with the
SEC.
These and other risks are described more fully
in Elevai’s filings with the Securities and Exchange Commission
(“SEC”), including the “Risk Factors” section of the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the SEC on March 29, 2024, and its other documents
subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, the Company undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
For media inquiries, please
contact:
Investor Relations
Contact:Tyler Troup, Circadian Group
IRIR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Sep 2023 to Sep 2024